Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride
暂无分享,去创建一个
Ulla Ruotsalainen | Kjell Någren | Juha O. Rinne | Arto Laihinen | Vesa Oikonen | K. Någren | V. Oikonen | J. Rinne | U. Ruotsalainen | A. Laihinen | H. Ruottinen | P. Lehikoinen | Pertti Lehikoinen | U. Rinne | Hanna Ruottinen | U. K. Rinne
[1] K. Jellinger,et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.
[2] G. Scatchard,et al. THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .
[3] C D Marsden,et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. , 1990, Brain : a journal of neurology.
[4] A. Antonini,et al. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease , 1994, Neurology.
[5] R S Frackowiak,et al. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. , 1993, Brain : a journal of neurology.
[6] L. Farde,et al. Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[7] K. L. Leenders,et al. Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers , 1988, Brain Research.
[8] Richard S. J. Frackowiak,et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.
[9] Michael J. Adam,et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease , 1985, Nature.
[10] K. Jellinger,et al. The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease , 1991, Journal of neuropathology and experimental neurology.
[11] C. Marsden,et al. Recent Developments in Parkinson's Disease , 1986 .
[12] G. Antoni,et al. Striatal kinetics of [11C]‐(+)‐nomifensine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease measured with positron emission tomography , 1990, Acta neurologica Scandinavica.
[13] P. Hartvig,et al. Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C‐N‐methyl‐spiperone , 1987, Acta neurologica Scandinavica.
[14] J. Rinne,et al. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra , 1989, Annals of neurology.
[15] S. Fahn. Unified Parkinson's Disease Rating Scale , 1987 .
[16] S. Snyder,et al. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. , 1977, Science.
[17] U Ruotsalainen,et al. PET study on striatal dopamine D2 receptor changes during the progression of early parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.
[18] S. Fahn. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .
[19] C. Halldin,et al. A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[20] T Jones,et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. , 1986, Journal of neurology, neurosurgery, and psychiatry.
[21] C. Nahmias,et al. Central Dopaminergic Pathways in Hemiparkinsonism Examined by Positron Emission Tomography , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[22] A. Lees,et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease , 1992, Neurology.
[23] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[24] H. Kimura,et al. Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels , 1993, Annals of neurology.
[25] J. Kebabian,et al. Multiple receptors for dopamine , 1979, Nature.
[26] H Lundqvist,et al. Monoamine re‐uptake sites in the human brain evaluated in vivo by means of 11C‐nomifensine and positron emission tomography: the effects of age and Parkinson's disease , 1988, Acta neurologica Scandinavica.
[27] M. Raichle,et al. MPTP‐induced up‐regulation of in vivo dopaminergic radioligand‐receptor binding in humans , 1987, Neurology.
[28] U Ruotsalainen,et al. Decrease in Human Striatal Dopamine D2 Receptor Density with Age: A PET Study with [11C]Raclopride , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[29] J. Rinne,et al. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.
[30] C. Patlak,et al. Nigrostriatal function in humans studied with positron emission tomography , 1989, Annals of neurology.
[31] D B Calne,et al. Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices , 1993, Annals of neurology.
[32] P. Spano,et al. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. , 1978, Advances in biochemical psychopharmacology.